Swedish Orphan Biovitrum
As of the edition of 20 October 2026, Swedish Orphan Biovitrum runs 22 drugs, 13 of them marketed; it is on route A at 1 target and on route B at 8 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 13 |
| Active | 1 |
| Went quiet | 4 |
| Stopped | 3 |
| Withdrawn from market | 1 |
| Total | 22 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Anakinra | Ends 2027 (orphan exclusivity) | 0 |
| Avatrombopag | Ends 2032 (exclusivity) | 2 |
| Pacritinib | Ends 2030 (patent) | 2 |
| Palifermin | Ended 2016 (computed from the first US licence) | 0 |
| Loncastuximab tesirine | Ends 2033 (computed from the first US licence) | 2 |
| Pegcetacoplan | Ends 2033 (patent) | 2 |
| Emapalumab | Ends 2030 (computed from the first US licence) | 1 |
| Nitisinone | none listed | 2 |
| Efmoroctocog alfa | Ended 2026 (computed from the first US licence) | 0 |
| Efanesoctocog alfa | Ends 2035 (computed from the first US licence) | 0 |
| Olezarsen | none listed | 1 |
| Eftrenonacog alfa | Ended 2026 (computed from the first US licence) | 0 |
| Palivizumab | Ended 2010 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 8 targets.
All 9 rows on route A or B
In the product9 company-target rows on route A or B; 6 are not shown here, and no score is.
See all 9 targets where Swedish Orphan Biovitrum needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 20 trials led
- Blood and lymph: 18 trials led
- Immune system: 8 trials led